Category Archives: Ulcerative Colitis

Fart. Trump. Continue reading →

Rome filed a civil lawsuit this week against over 30 companies that own or operate carpet-related facilities in Dalton. The lawsuit, filed Tuesday in Floyd County Superior Court, contends the companies including 3M, DuPont, Shaw Industries and others knew the perfluorinated compounds used in their manufacturing were toxic Continue reading →

PARIS--(BUSINESS WIRE)--Regulatory News: ABIVAX SA (Euronext Paris: FR0012333284 ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announced that the French National Regulatory Authority (ANSM) has approved the ABX464-103 Phase 2b study of its lead product candidate ABX464 with once a day convenient oral dosing for treatment of patients with moderate to severe active ulcerative colitis (UC). Prof. Continue reading →

Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohns disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract. Historically IBD has been predominantly seen in industrialized countries, with the highest reported prevalence values in Europe and North America. Continue reading →

Pfizer Inc. Continue reading →

Crohn's & Colitis Foundation's IBD Ventures award supports development of Thetis' novel first-in-class Resolvin oral therapy (TP-317) for treatment of ulcerative colitis and Crohn's disease BRANFORD, CT / ACCESSWIRE / November 19, 2019 / Thetis Pharmaceuticals ("Thetis"), a biopharmaceutical company developing novel therapies for gastrointestinal diseases, today announced receipt of funding from the Crohn's & Colitis Foundation's IBD Ventures program to support development of TP-317, a first-in-class, oral therapy for inflammatory bowel disease (IBD). The active agent in TP-317 is Resolvin E1, an endogenous immuno-resolvent first discovered by Dr. Continue reading →

Anti-inflammatory drugs are often the first step in the treatment of ulcerative colitis. They include: 5-aminosalicylates. Examples of this type of medication includesulfasalazine (Azulfidine), mesalamine (Asacol HD, Delzicol, others), balsalazide (Colazal) and olsalazine (Dipentum) Continue reading →

Medically reviewed by Jeffrey A. Meyerhardt, MD, MPH Irritable bowel syndrome (IBS) is a chronic disorder in which the large intestine undergoes abnormal contractions, producing abdominal pain, cramps, diarrhea, constipation, or a mix of these symptoms. (It is a different condition from inflammatory bowel disease (IBD), which most often occurs as ulcerative colitis or Crohns disease.) Colorectal cancer, which involves the uncontrolled growth of cells in a portion of the large intestine called the colon or rectum, can produce similar symptoms, so it is important to be aware of the differences between the two conditions. Continue reading →

The Ulcerative Colitis Market report gives an astonishing source to analyze the Ulcerative Colitis market and other fundamental subtleties identifying with it. The examination uncovers the general evaluation and associated ideas of the Ulcerative Colitis market Continue reading →

New York City, NY: November 16, 2019 Published via (Wired Release) The report on Global Ulcerative Colitis Treatment Market delivers recent industry information and highlights several trends impacting the growth of the market. Likewise, it highlights the top vendors, different analysis techniques, and drivers with a market forecast from 2020 to 2029. Continue reading →